Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.1%

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price dropped 3.1% during trading on Tuesday . The stock traded as low as $42.88 and last traded at $43.15. Approximately 706,634 shares were traded during mid-day trading, a decline of 12% from the average daily volume of 804,854 shares. The stock had previously closed at $44.52.

Analyst Upgrades and Downgrades

GPCR has been the subject of several research reports. BMO Capital Markets boosted their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, June 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, July 1st. JPMorgan Chase & Co. began coverage on shares of Structure Therapeutics in a research report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price objective for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Friday, May 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $85.25.

Structure Therapeutics Price Performance

The firm’s 50-day moving average price is $41.96 and its 200 day moving average price is $41.55. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -56.75 and a beta of -3.59.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. On average, analysts predict that Structure Therapeutics Inc. will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in GPCR. Wellington Management Group LLP increased its position in shares of Structure Therapeutics by 312.6% in the third quarter. Wellington Management Group LLP now owns 867,579 shares of the company’s stock worth $43,743,000 after acquiring an additional 657,310 shares in the last quarter. TrueMark Investments LLC acquired a new stake in Structure Therapeutics during the 4th quarter valued at $1,073,000. Raymond James & Associates acquired a new stake in Structure Therapeutics during the 4th quarter valued at $233,000. China Universal Asset Management Co. Ltd. grew its holdings in Structure Therapeutics by 208.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock valued at $177,000 after purchasing an additional 2,939 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Structure Therapeutics during the 4th quarter valued at $1,960,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.